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alpha therapy for hepatitis C: case report
Victoria Yee-May Ling1*, Marianne Mortimore2 and David J Serisier1,3,4Abstract
Interferon alpha (IFNα) has immune stimulatory actions implicated in its pulmonary toxicities. We describe
deterioration of idiopathic pulmonary fibrosis (IPF) associated with IFNα treatment for chronic hepatitis C in a
58 year old woman culminating in a fatal suspected acute exacerbation of IPF (AE-IPF). Caution should be exercised
in the use of IFNα in subjects with concomitant IPF given its known immunostimulatory effects and possible role in
this suspected AE-IPF.
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Pulmonary toxicity is a recognised complication of in-
terferon alpha (IFNα), thought to be related to its
immunostimulatory effects. IFNα has been shown to
influence the immune system along multiple pathways
including augmentation of proinflammatory and pro-
fibrotic cytokines (Midturi et al. 2004). Interstitial pneu-
monitis is the most commonly documented pulmonary
toxicity of IFNα (Midturi et al. 2004), but potential
deterioration of existing interstitial lung disease needs to
be highlighted. We describe a case of progression of
usual interstitial pneumonia (UIP)/idiopathic pulmonary
fibrosis (IPF) during IFNα treatment, which culminated
in a fatal acute exacerbation of IPF (AE-IPF).Case description
A 58 year old woman with probable UIP/IPF and hepa-
titis C virus (HCV)-related Child-Pugh A liver cirrhosis
developed an oesophageal variceal bleed. Hepatitis C
was associated with moderate inflammatory activity
(Metavir score A3F4), previous hepatic decompensation
with ascites and F3 oesophageal varices treated with
prophylactic ligation. She had a history of tobacco-* Correspondence: viki_ling@hotmail.com
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Eighteen months before admission, high-resolution com-
puted tomography (HRCT) of the chest demonstrated
lower zone predominant subpleural interstitial fibrosis
with honeycombing consistent with UIP/IPF (see
Figure 1a), in addition to centrilobular emphysema.
Five months before admission, she commenced
pegylated-interferon alpha-2α and ribavirin. Lung func-
tion tests repeated after 1 month of therapy showed 6%
reduction in forced vital capacity (FVC) (see Table 1),
unassociated with ascites at that time. Pulmonary HRCT
after 2 months of therapy showed deterioration of fi-
brotic changes (see Figure 1b).
On admission, she received intravenous octreotide,
prophylactic ceftriaxone and endoscopic variceal banding.
On day 3, she developed progressive hypoxaemia, requi-
ring high flow nasal prong oxygen to achieve oxyhaemo-
globin saturations of 96%. She was febrile to 38.3°C. HRCT
of the chest demonstrated diffuse ground-glass change
superimposed on markedly deteriorated bilateral pulmon-
ary fibrosis with honeycomb changes (see Figure 2). Intra-
venous piperacillin/tazobactam, vancomycin, tobramycin
and azithromycin were commenced. Sputum specimens
cultured Pseudomonas aeruginosa and non-multiresistant
methicillin-resistant Staphylococcus aureus (nmMRSA).
On day 6, intravenous hydrocortisone was commenced.
On Day 7, bronchoalveolar lavage was performed andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Serial chest HRCT images in relation to IFNα therapy. Progression of subpleural interstitial fibrosis and honeycombing from (a)
9 months prior to the current presentation, prior to commencement of IFNα to (b) 3 months prior, 2 months after commencing IFNα therapy.
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for all other pathogens including Pneumocystis jiroveci
(carinii). Transthoracic echocardiogram demonstrated
normal left ventricular function. On day 10, there was fur-
ther deterioration in oxygenation and she required high
flow oxygen via mask to achieve oxygen saturations of
90%. Pulse intravenous methylprednisolone was com-
menced however her respiratory status continued to de-
teriorate. Escalation of therapy including endotracheal
intubation was thought to be futile and she died on day 14.
Discussion and evaluation
The immunostimulatory properties of IFNα and its
recognised risks of pulmonary toxicity including pneu-
monitis create a strong case for implicating IFNα in
potentiating the current deterioration of IPF with a pos-
sible contribution to the subsequent suspected AE-IPF.
This patient demonstrated objective progression of her
probable UIP soon after commencing IFNα, with bothTable 1 Respiratory function tests of the patient with
times in reference to her admission
9 months earlier 4 months earlier
FEV1 - L (% predicted) 2.26 (88) 2.13 (83)
FVC - L (% predicted) 3.60 (111) 3.38 (105)
FEV1/FVC (% predicted) 0.63 (79) 0.63 (80)
TLC – L (% predicted) 5.38 (106) 5.05 (100)
DLCO/VA - mL/min/mmHg/L
(% predicted)
1.62 (35) 1.64 (35)
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; TLC,
total lung capacity; DLCO, carbon monoxide diffusing capacity; VA,
alveolar volume.physiologic (within 1 month) and radiologic (within
2 months) evidence of deterioration. The 6% decline in
FVC was felt to be within the limits of variability, although
recent data have shown that FVC decline of >5% predicts
a doubling of one year mortality (Zappala et al. 2010).
The acute respiratory decline during the described
admission was suspected to be secondary to AE-IPF.
Although P. aeruginosa and nmMRSA were isolated
from respiratory specimens at the time, the patient re-
ceived appropriate antibiotic therapy promptly at onset
(prior to culture of the organisms) and subsequent bron-
choscopy (performed because of progressive hypoxia)
did not reculture Pseudomonas. Furthermore, her cli-
nical course was marked by relentlessly progressive,
antibiotic-unresponsive, hypoxic respiratory failure with-
out evidence of sepsis, features much more consistent
with AE-IPF than nmMRSA pneumonia. While exclu-
sion of infection forms part of Collard’s proposed criteria
for definition of AE-IPF (Collard et al. 2007), infectious
agents have been found in up to one-third of subjects
with this diagnosis (Borchers et al. 2011) and others have
argued that diffuse alveolar damage superimposed upon
IPF represents a common endpoint that may be the re-
sult of a range of potential triggers, including infection
(Corte and Wells 2010).
Conclusions
Given that IFNα is now part of standard therapy for
chronic HCV infection and the rising incidence of UIP/
IPF in Western countries (Navaratnam et al. 2011), it is
likely that subjects with UIP/IPF will be increasingly
exposed to this therapy. The possibility that IFNα may
result in significant, potentially fatal deterioration in
Figure 2 Serial chest HRCT images in relation to the suspected AE-IPF. HRCT performed during the exacerbation (c) and (d) demonstrates
diffuse ground glass opacity with marked progression of the underlying fibrosis and honeycombing compared with 3 months prior (a) and (b).
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prior to embarking upon this therapy in these subjects.
Whilst the current case in no way demonstrates causality,
we would advise close monitoring and a low threshold for
cessation of this therapy in the event of deterioration.
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